SARomics Biostructures and Red Glead Discovery Enters into Drug Discovery Collaboration
News Oct 25, 2012
SARomics Biostructures and Red Glead Discovery have announced that they have entered into a drug discovery collaboration.
Targeting proteins involved in epigenetic mechanisms (the cellular processes associated with the modification of chromatin) have emerged as an important new therapeutic opportunity for treating cancer, diabetes, inflammatory diseases and more.
By merging the unique and highly complementary capabilities of the two companies, an efficient and versatile fragment-based lead discovery (FBLD) platform is enabled.
The advanced structural biology platform and expertise contributed by SARomics Biostructures are combined with the bioassay technology and medicinal chemistry skills of Red Glead Discovery.
The scientific excellence of the alliance is reflected by the track record of Red Glead Discovery for delivery of lead compounds and the established platform for structure-based drug design implemented by SARomics Biostructures.
For the project, the companies will share costs and the generated intellectual property rights.
Project progress and the discovery of lead compounds will be effectuated by utilization of FBLD, which is a powerful alternative to costly and resource-intensive high-throughput screening (HTS) campaigns.
At this stage of the project, the collaboration will be run without external financing.
Björn Walse, CEO of SARomics Biostructures, said “We are excited about the opportunity to work with Red Glead Discovery on this frontline project that clearly leverages the competitiveness of both companies. We see this initiative as highly complementary to SARomics’ other collaborations, such as those within KINOMED, which focus on protein kinase off-the-shelf crystal structures and fragment complexes.”
Johan Evenäs, CEO of Red Glead Discovery, added “I am convinced that we have a perfect match of competences and experiences enabling a project that would have been difficult for either company alone at this stage. We expect the close proximity of our two companies within the Lund Life Science Incubator at Medicon Village to further facilitate effective collaboration.”